Search Result

Results for "

lymphocyte-mediated

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Influenza Virus (1) Isotope-Labeled Compounds (2) LPL Receptor (3)
By Research Areas:	Inflammation/Immunology (3)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Targets Recommended: LAG-3 CTLA-4

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10569

Ponesimod 3 Publications Verification ACT-128800	LPL Receptor	Inflammation/Immunology
Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

HY-10569S1

Ponesimod-d7 ACT-128800-d₇	Isotope-Labeled Compounds	Others
Ponesimod-d₇ (ACT-128800-d₇) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d₇ (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod-d₇ activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod-d₇ can protect against lymphocyte-mediated tissue inflammation .

HY-10569R

Ponesimod (Standard) ACT-128800 (Standard)	LPL Receptor	Inflammation/Immunology
Ponesimod (Standard) is the analytical standard of Ponesimod. This product is intended for research and analytical applications. Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation[1][2][3].

HY-10569S

Ponesimod-d4 ACT-128800-d₄	Isotope-Labeled Compounds LPL Receptor	Others
Ponesimod-d₄ (ACT-128800-d₄) is the deuterium labeled Ponesimod (HY-10569) . Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

HY-P1835

CEF8, Influenza Virus NP (383-391)	Influenza Virus	Inflammation/Immunology
CEF8, Influenza Virus NP (383-391), an influenza A virus nucleoprotein containing residues 383 to 391, is the most important HLA-B ^2705-restricted epitope in the nucleoprotein of influenza A viruses and is associated with escape from cytotoxic T lymphocytes-mediated* immunity .

Cat. No.	Product Name	Target	Research Area

HY-P1835

CEF8, Influenza Virus NP (383-391)	Influenza Virus	Inflammation/Immunology
CEF8, Influenza Virus NP (383-391), an influenza A virus nucleoprotein containing residues 383 to 391, is the most important HLA-B ^2705-restricted epitope in the nucleoprotein of influenza A viruses and is associated with escape from cytotoxic T lymphocytes-mediated* immunity .

Cat. No.	Product Name	Chemical Structure

HY-10569S1

Ponesimod-d7
Ponesimod-d₇ (ACT-128800-d₇) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d₇ (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod-d₇ activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod-d₇ can protect against lymphocyte-mediated tissue inflammation .

Ponesimod-d7

Ponesimod-d₇ (ACT-128800-d₇) is the deuterium-labeled Ponesimod (HY-10569). Ponesimod-d₇ (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod-d₇ activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod-d₇ can protect against lymphocyte-mediated tissue inflammation .

HY-10569S

Ponesimod-d4
Ponesimod-d₄ (ACT-128800-d₄) is the deuterium labeled Ponesimod (HY-10569) . Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

Ponesimod-d4

Ponesimod-d₄ (ACT-128800-d₄) is the deuterium labeled Ponesimod (HY-10569) . Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P₁, with an IC₅₀ of 6 nM in a radioligand binding assay. Ponesimod activates S1P₁-mediated signal transduction with high potency (EC₅₀=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.